The sale is pre-planned under a 10b5-1 plan adopted a year ago, so it carries no new information about the company's prospects. Monitor for any subsequent Form 4 filings to confirm execution, but no immediate market impact is expected.
Price Chart
Executive Summary
Director Helen Collins filed a Form 144 notice of intent to sell 15,000 shares of Enliven Therapeutics (ELVN), with an estimated aggregate market value of $559,800. The sale is to be executed under a Rule 10b5-1 trading plan adopted on October 19, 2025, indicating the sale was pre-planned and not based on recent material non-public information. The filing is a routine advance notice by a director and does not convey new information about the company's operations or outlook.
Key Facts
- Director Helen Louise Collins filed a Form 144 to sell 15,000 shares of Enliven Therapeutics common stock.
- Estimated aggregate market value of the proposed sale is $559,800.
- The sale is to be executed through Jefferies LLC.
- The sale is made pursuant to a Rule 10b5-1 trading plan adopted on October 19, 2025.
- The filing date is October 19, 2026.
- The proposed sale represents approximately 0.02% of the company's 73,000,000 shares outstanding (based on the filing's stated outstanding share count).
Financial Impact
Proposed sale of 15,000 shares valued at $559,800, representing a small fraction of the company's market capitalization.
Risk Factors
- Insider selling, even under a 10b5-1 plan, can be perceived negatively by some market participants.
- The filing does not disclose the insider's remaining holdings, so the proportional significance of the sale is unclear.
Investment Themes
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 144 Filing (Primary) | 0001974158-26-000109 |
| Document: 0001974158-26-000109-index.html | 0001974158-26-000109 |
| Document: 0001974158-26-000109.txt | 0001974158-26-000109 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 21, 2026 5d ago | Insider Cluster | $41.93 | awaiting T+5 | — | $43.94 (+4.79%) |
Oct 19, 2026 7d ago | 144 | $41.25 | awaiting T+5 | — | $43.94 (+6.52%) |
Oct 16, 2026 10d ago | 3 | $38.70 $41.49 | ▲ +7.21% | ▲ +7.35% | $43.94 (+13.54%) |
Oct 14, 2026 12d ago | 8-K | $39.33 $41.93 | ▲ +6.61% | ▲ +7.63% | $43.94 (+11.72%) |
Sep 21, 2026 5w ago | Insider Cluster | $48.19 $46.51 | ▼ −3.49% | ▼ −2.30% | $43.94 (−8.82%) |
Sep 4, 2026 7w ago | 144 | $59.32 $54.43 | ▼ −8.24% | ▼ −7.03% | $43.94 (−25.93%) |
Aug 19, 2026 9w ago | Insider Cluster | $58.97 $60.50 | ▲ +2.59% | ▲ +1.48% | $43.94 (−25.49%) |
Aug 9, 2026 11w ago | Institutional Cluster | $59.42 $59.54 | ▲ +0.19% | ▲ +0.24% | $43.94 (−26.05%) |
Jul 21, 2026 13w ago | Insider Cluster | $52.85 $52.97 | ▲ +0.23% | ▲ +2.63% | $43.94 (−16.86%) |
Jun 22, 2026 18w ago | 144 | $48.60 $50.85 | ▲ +4.63% | ▲ +3.62% | $43.94 (−9.59%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers